{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:18:08Z","timestamp":1788164288496,"version":"build-2803163510"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"73","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The success of prophylactic human papillomavirus (HPV) vaccination in reducing disease burden came with an epidemiological concern: HPV type replacement, the potential compensatory increase of nonvaccine targeted HPV types following the elimination of HPV16 and 18. Postvaccination surveillance across several countries suggests some signs of increase in the nonvaccine targeted HPV types, which may be explainable because of type replacement. However, should HPV type replacement be occurring, it is unlikely to generate disease replacement because of the significantly lower oncogenic potential of nonvaccine targeted HPV types. The modernization of screening to align with this new risk profile is necessary. Personalized screening protocols based on individual risk profiles informed by primary HPV testing with extended genotyping and future molecular triage to accurately risk-stratify HPV types are necessary in the postvaccination era.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgag011","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:11:20Z","timestamp":1777637480000},"page":"148-154","source":"Crossref","is-referenced-by-count":0,"title":["Evidence for type replacement as a consequence of vaccination and implications for cervical screening"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-4734","authenticated-orcid":false,"given":"Penelope","family":"Gray","sequence":"first","affiliation":[{"name":"Center for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-363X","authenticated-orcid":false,"given":"Karolina","family":"Louvanto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine and Health Technology, Tampere University , Tampere,","place":["Finland"]},{"name":"Department of Obstetrics and Gynecology, Tampere University Hospital , Tampere,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026083104014439700_lgag011-B1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"2026083104014439700_lgag011-B2","first-page":"1","article-title":"International Agency for Research on Cancer (IARC) working group on the evaluation of carcinogenic risks to humans. biological agents","volume":"100","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"2026083104014439700_lgag011-B3","author":"International Human Papillomavirus Reference Center","year":"2025"},{"key":"2026083104014439700_lgag011-B4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"2026083104014439700_lgag011-B5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2013.07.015","article-title":"A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types","volume":"445","author":"Bzhalava","year":"2013","journal-title":"Virology"},{"key":"2026083104014439700_lgag011-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1098\/rsif.2007.0236","article-title":"Vaccine-induced pathogen strain replacement: what are the mechanisms?","volume":"5","author":"Martcheva","year":"2008","journal-title":"J R Soc Interface"},{"key":"2026083104014439700_lgag011-B7","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/ijc.32919","article-title":"Identification of HPV genotypes causing cervical precancer using tissue-based genotyping","volume":"146","author":"Venetianer","year":"2020","journal-title":"Int J Cancer"},{"key":"2026083104014439700_lgag011-B8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(22)00291-1","article-title":"Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial","volume":"23","author":"Shing","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026083104014439700_lgag011-B9","doi-asserted-by":"crossref","first-page":"djv185","DOI":"10.1093\/jnci\/djv185","article-title":"Interactions between high- and low-risk HPV types reduce the risk of squamous cervical cancer","volume":"107","author":"Sundstr\u00f6m","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014439700_lgag011-B10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ejca.2003.11.032","article-title":"Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri","volume":"40","author":"Luostarinen","year":"2004","journal-title":"Eur J Cancer"},{"key":"2026083104014439700_lgag011-B11","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"\u201cSerotype replacement in disease after pneumococcal vaccination.\u201d","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet (London, England)"},{"key":"2026083104014439700_lgag011-B12","doi-asserted-by":"crossref","first-page":"e1001517","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"2026083104014439700_lgag011-B13","author":"Gause","year":"1944"},{"key":"2026083104014439700_lgag011-B14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1098\/rspb.2001.1897","article-title":"Parapoxvirus causes a deleterious disease in red squirrels associated with UK population declines","volume":"269","author":"Tompkins","year":"2002","journal-title":"Proc Biol Sci"},{"key":"2026083104014439700_lgag011-B15","first-page":"20172603","article-title":"The enemy of my enemy is my friend: native pine marten recovery reverses the decline of the red squirrel by suppressing grey squirrel populations","volume":"285","author":"Sheehy","year":"2018","journal-title":"Proc Biol Sci"},{"key":"2026083104014439700_lgag011-B16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/infdis\/jir709","article-title":"Multiple human papillomavirus infections and type competition in men","volume":"205","author":"Rositch","year":"2012","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B17","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ejca.2011.10.010","article-title":"Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study","volume":"48","author":"Carozzi","year":"2012","journal-title":"Eur J Cancer"},{"key":"2026083104014439700_lgag011-B18","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.vaccine.2012.12.084","article-title":"Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark","volume":"31","author":"Goldman","year":"2013","journal-title":"Vaccine"},{"key":"2026083104014439700_lgag011-B19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/aje\/kwt018","article-title":"Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination","volume":"178","author":"Tota","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2026083104014439700_lgag011-B20","doi-asserted-by":"crossref","first-page":"e0166329","DOI":"10.1371\/journal.pone.0166329","article-title":"Epidemiologic evaluation of human papillomavirus type competition and the potential for type replacement post-vaccination","volume":"11","author":"Tota","year":"2016","journal-title":"PLoS One"},{"key":"2026083104014439700_lgag011-B21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/jiw215","article-title":"Cervical infection with vaccine-associated Human Papillomavirus (HPV) genotypes as a predictor of acquisition and clearance of other HPV infections","volume":"214","author":"Tota","year":"2016","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1055-9965.EPI-09-0983","article-title":"Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys","volume":"19","author":"Vaccarella","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026083104014439700_lgag011-B23","doi-asserted-by":"crossref","first-page":"e71617","DOI":"10.1371\/journal.pone.0071617","article-title":"Patterns of human papillomavirus types in multiple infections: an analysis in women and men of the high throughput human papillomavirus monitoring study","volume":"8","author":"Vaccarella","year":"2013","journal-title":"PLoS One"},{"key":"2026083104014439700_lgag011-B24","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/aje\/kwu038","article-title":"Population- and type-specific clustering of multiple HPV types across diverse risk populations in the Netherlands","volume":"179","author":"Mollers","year":"2014","journal-title":"Am J Epidemiol"},{"key":"2026083104014439700_lgag011-B25","doi-asserted-by":"crossref","first-page":"20180298","DOI":"10.1098\/rstb.2018.0298","article-title":"Capturing multiple-type interactions into practical predictors of type replacement following human papillomavirus vaccination","volume":"374","author":"Man","year":"2019","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2026083104014439700_lgag011-B26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365540903501608","article-title":"Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes","volume":"42","author":"Palmroth","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"2026083104014439700_lgag011-B27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/aje\/kww152","article-title":"Bias due to correlation between times-at-risk for infection in epidemiologic studies measuring biological interactions between sexually transmitted infections: a case study using human papillomavirus type interactions","volume":"184","author":"Malag\u00f3n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2026083104014439700_lgag011-B28","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2012.11.098","article-title":"Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach","volume":"31","author":"Pons-Salort","year":"2013","journal-title":"Vaccine"},{"key":"2026083104014439700_lgag011-B29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/infdis\/jis494","article-title":"Reevaluation of epidemiological data demonstrates that it is consistent with cross-immunity among human papillomavirus types","volume":"206","author":"Durham","year":"2012","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B30","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026083104014439700_lgag011-B32","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1473-3099(13)70024-0","article-title":"Cross protection against HPV might prevent type replacement","volume":"13","author":"Verdenius","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2026083104014439700_lgag011-B34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/infdis\/jiz280","article-title":"Bivalent Human Papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18","volume":"220","author":"Bogaards","year":"2019","journal-title":"J Infect Dis."},{"key":"2026083104014439700_lgag011-B35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/infdis\/jiaa032","article-title":"Human papillomavirus genotype replacement: still too early to tell?","volume":"224","author":"Man","year":"2021","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B36","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1073\/pnas.94.12.6571","article-title":"Vaccination against colonizing bacteria with multiple serotypes","volume":"94","author":"Lipsitch","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026083104014439700_lgag011-B37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2105\/AJPH.94.3.416","article-title":"Pitfalls of and controversies in cluster randomization trials","volume":"94","author":"Donner","year":"2004","journal-title":"Am J Public Health"},{"key":"2026083104014439700_lgag011-B38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"2026083104014439700_lgag011-B39","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1016\/j.vaccine.2023.10.002","article-title":"The impact of over ten years of HPV vaccination in England: surveillance of type-specific HPV in young sexually active females","volume":"41","author":"Checchi","year":"2023","journal-title":"Vaccine"},{"key":"2026083104014439700_lgag011-B40","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1093\/infdis\/jiae455","article-title":"Changes in Genital Human Papillomavirus (HPV) prevalence during 12 years of girls-only bivalent hpv vaccination: results from a biennial repeated cross-sectional study","volume":"231","author":"Kusters","year":"2025","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B41","doi-asserted-by":"crossref","first-page":"2400820","DOI":"10.2807\/1560-7917.ES.2025.30.27.2400820","article-title":"Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study","volume":"30","author":"Nonboe","year":"2025","journal-title":"Euro Surveill"},{"key":"2026083104014439700_lgag011-B42","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/ijc.31281","article-title":"Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II)","volume":"142","author":"Gray","year":"2018","journal-title":"Int J Cancer"},{"key":"2026083104014439700_lgag011-B43","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.chom.2023.10.001","article-title":"Ecological diversity profiles of non-vaccine-targeted HPVs after gender-based community vaccination efforts","volume":"31","author":"Pimenoff","year":"2023","journal-title":"Cell Host Microbe"},{"key":"2026083104014439700_lgag011-B44","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1002\/ijc.33169","article-title":"Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage","volume":"147","author":"Gray","year":"2020","journal-title":"Int J Cancer"},{"key":"2026083104014439700_lgag011-B45","doi-asserted-by":"crossref","first-page":"127576","DOI":"10.1016\/j.vaccine.2025.127576","article-title":"Evaluation of possible human papillomavirus (HPV) type replacement after vaccine introduction, overall and by race\/ethnicity, United States","volume":"62","author":"Brewer","year":"2025","journal-title":"Vaccine"},{"key":"2026083104014439700_lgag011-B46","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human Papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.vaccine.2018.11.075","article-title":"Age-specific HPV prevalence among 116,052 women in Australia\u2019s renewed cervical screening program: a new tool for monitoring vaccine impact","volume":"37","author":"Brotherton","year":"2019","journal-title":"Vaccine"},{"key":"2026083104014439700_lgag011-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid2701.191364","article-title":"Impact of human papillomavirus vaccination, Rwanda and Bhutan","volume":"27","author":"Baussano","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2026083104014439700_lgag011-B49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3201\/eid2201.150791","article-title":"Human papillomavirus vaccination at a time of changing sexual behavior","volume":"22","author":"Baussano","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2026083104014439700_lgag011-B50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1055-9965.EPI-11-0761","article-title":"Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer","volume":"20","author":"Arnheim Dahlstr\u00f6m","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026083104014439700_lgag011-B51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1055-9965.EPI-14-0566","article-title":"Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens","volume":"24","author":"Tota","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026083104014439700_lgag011-B52","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jnci\/djad263","article-title":"Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation","volume":"116","author":"Palmer","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014439700_lgag011-B53","doi-asserted-by":"crossref","first-page":"e1004304","DOI":"10.1371\/journal.pmed.1004304","article-title":"Impact of cervical screening by human papillomavirus genotype: population-based estimations","volume":"20","author":"Wang","year":"2023","journal-title":"PLoS Med"},{"key":"2026083104014439700_lgag011-B54","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1093\/infdis\/jiaf032","article-title":"Population-based age-period-cohort analysis of declining human papillomavirus prevalence","volume":"231","author":"Gray","year":"2025","journal-title":"J Infect Dis"},{"key":"2026083104014439700_lgag011-B55","doi-asserted-by":"crossref","first-page":"djw216","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014439700_lgag011-B56","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ijc.35435","article-title":"Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? A modelling study using cohort effects","volume":"157","author":"Kaljouw","year":"2025","journal-title":"Int J Cancer"},{"key":"2026083104014439700_lgag011-B57","doi-asserted-by":"crossref","first-page":"950610","DOI":"10.3389\/fpubh.2022.950610","article-title":"Which is the best management for women with normal cervical cytologic findings despite positivity for non-16\/18 high risk human papillomaviruses?","volume":"10","author":"Wu","year":"2022","journal-title":"Front Public Health"},{"key":"2026083104014439700_lgag011-B58","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1016\/S2468-2667(24)00218-4","article-title":"Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden","volume":"9","author":"Wang","year":"2024","journal-title":"Lancet Public Health"},{"key":"2026083104014439700_lgag011-B59","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ijc.32973","article-title":"Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening","volume":"147","author":"Cuzick","year":"2020","journal-title":"Int J Cancer"},{"key":"2026083104014439700_lgag011-B60","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.35044","article-title":"Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions","volume":"155","author":"Louvanto","year":"2024","journal-title":"Int J Cancer"},{"key":"2026083104014439700_lgag011-B61","doi-asserted-by":"crossref","first-page":"e1004494","DOI":"10.1371\/journal.pmed.1004494","article-title":"Human papillomavirus genotype and cycle threshold value from self-samples and risk of high-grade cervical lesions: a post hoc analysis of a modified stepped-wedge implementation feasibility trial","volume":"21","author":"Lei","year":"2024","journal-title":"PLoS Med"},{"key":"2026083104014439700_lgag011-B62","doi-asserted-by":"crossref","first-page":"e70936","DOI":"10.1002\/jmv.70936","article-title":"International","volume":"98","author":"Yilmaz","year":"2026","journal-title":"J Med Virol"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/148\/70870250\/lgag011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/148\/70870250\/lgag011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:01:59Z","timestamp":1788163319000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2026\/73\/148\/8776085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":62,"journal-issue":{"issue":"73","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgag011","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]}}}